PPMD Names Massachusetts General Hospital a Certified Duchenne Care Center
Parent Project Muscular Dystrophy has named Massachusetts General Hospital (MGH) our sixth Certified Duchenne Care Center, recognizing the Hospital’s dedication to improving care for people living with Duchenne.
End Duchenne eNews: Finding Strength
Catch up on the latest research and community updates in this month's End Duchenne eNews!
Upcoming Webinar: Combination Therapies
PPMD is hosting a webinar on Wednesday, December 17th at 1PM EST to discuss combination therapies -- a group of research projects that, together, we believe will help us take a big step forward in ending Duchenne. As you know, combination therapies are the focus of PPMD’s annual holiday campaign.
Let's Combine Our Efforts
This holiday season, we’re asking for your help in reaching an ambitious goal of raising $400,000 to advance combination therapies in Duchenne. In less than two weeks we have already raised $128,000. But now, thanks to the generosity of two foundations, we can get to our goal that much quicker! Donate today and have your gift matched dollar for dollar.
PPMD To Collaborate With Catabasis Pharmaceuticals, Inc. On CAT-1004 Development
PPMD announced today a collaboration with Catabasis Pharmaceuticals, Inc. to assist in a Phase 2 clinical trial of its CAT-1004 product candidate for the treatment of patients with Duchenne. As part of this collaboration, PPMD will provide funding to support participant travel. The trial is expected to begin in the first half of 2015.
PPMD Calls for Greater Transparency and Accountability of FDA Patient Engagement Efforts
PPMD is convening a Congressional Briefing tomorrow at noon to present reform proposals for the 21st Century Cures Initiative. Urge your members of Congress to join us!
PPMD Awards Akashi Therapeutics, Inc. $500,000 Grant
PPMD has awarded Akashi Therapeutics, Inc. (Akashi) a $500,000 grant to fund clinical trials to test the safety and efficacy of an investigational new drug known as HT-100 (delayed-release halofuginone).
ABLE Act Changes Disability Landscape –
Two generous Duchenne foundations will match your donation dollar for dollar to help us reach our goal: $400,000 to advance combination of therapies that, together, can make a difference for every person with Duchenne.
Make a tax-deductible donation and give us the strength we need to end Duchenne.